The biomarker data is now being run and put into the electronic data capture system before the data can be locked for statistical analysis. Should be done in the next few days then QC before formal data lock so the analysis will be very short
I wouldn't be surprised, based on what smart investors that have done DD already know about the end points and biomarkers if it takes more than an hour or a day to do the analysis. There are only 3 end points and 3 biomarkers. All the work is upfront on deciding on endpoints, data entry and QA. The secondary endpoints aren't even subjective or debatable.
Some may see the readout as a lotto play. You either win or lose and nothing in-between. Unless the majority of those that didn't get Tollovir somehow recovered quickly and/or were doing cartwheels out the hospital door there is a lot of opportunity here in my opinion.
Todos is going down the hardest road (hospitalized patients) where others failed. Still have the mild and moderate people with Covid aces to play.
Something to think about...
Zicam was sold for 1/2 billion in 2020 and they only do nasal congestion, cold, and allergy relief.